The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $662,516 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to evaluate how fractionated radiation affects drug delivery within the tumor microenvironment. The 5-year project aims to quantify how local radiation reshapes the tumor microenvironment to influence passive drug delivery, and test whether long-circulating chemotherapy can synergistically and safely improve responses when combined with standard chemoradiotherapy. Preliminary studies have shown how new chemical strategies can activate long-circulating drug-conjugates in situ following radiation exposure, leading to selective drug action and synergistic efficacy. This research will provide a foundation for understanding how cellular and molecular responses to fractionated radiation impact drug delivery, and establish the basis for clinical translation of radiation-enhanced therapeutics.
Generated 3/25/25, 3:15 AM